Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Fig. 4

Proportion of patients on treatment experiencing gout flares during the pegloticase + methotrexate treatment period. The mean number of flares during weeks 0–12 and weeks 37–52 was 4.2 ± 2.3 (range 1 − 8) and 2.5 ± 0.7 (range 2 − 3), respectively

Back to article page